GSK Partners With Zhifei to Boost Shingles Vaccine Availability in China
By Michael Susin
GSK said it has an exclusive agreement with Chongqing Zhifei Biological Products to co-promote its shingles vaccine Shingrix in China.
The British pharmaceutical giant on Monday said that Zhifei will have exclusive rights to import and distribute Shingrix in the country for an initial three-year period starting from Jan. 1.
The deal will significantly extend the availability of the vaccine to healthcare professionals and over 30,000 points of vaccination, it said.
Zhifei is the largest Chinese vaccine company by revenue, GSK said.
The partnership will also support potential future co-development and commercialization of GSK's respiratory syncytial virus vaccine Arexvy in the country.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
October 09, 2023 02:30 ET (06:30 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk